Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

  • Published Date : May 13, 2026
  • Updated On : September 5, 2026
  • Pages : 154

Arrhythmogenic Right Ventricular Cardiomyopathy Market Outlook and Forecast

Thelansis’s “Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Arrhythmogenic Right Ventricular Cardiomyopathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Arrhythmogenic Right Ventricular Cardiomyopathy Overview

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited arrhythmogenic cardiomyopathy characterized by progressive myocardial loss with fibrotic and fibro-fatty replacement, ventricular arrhythmias, and risk of sudden cardiac death, with heart failure developing in some patients as the disease advances. Current management focuses on reducing arrhythmic and heart-failure risk through exercise restriction, pharmacologic therapy, and ICD implantation in appropriately selected patients, while advanced heart failure may require transplantation. However, these strategies do not directly correct the underlying genetic defect, and no approved disease-modifying therapy currently exists. This has driven an emerging precision-genetics landscape centered on PKP2, the most common genetic cause of aggressive ARVC. Several AAV-based PKP2 gene-replacement programs have entered early clinical development, including TN-401, LX2020, and RP-A601. TN-401 is being evaluated in a Phase 1b/2 study, and on September 14, 2026, it received FDA RMAT designation following interim data showing reduced arrhythmia burden. Other molecular strategies targeting fibrosis and downstream disease pathways remain largely preclinical. For stakeholders, ARVC represents an important precision-cardiology frontier in which the key opportunity is to move beyond prevention of arrhythmic consequences toward durable modification of the underlying genetic disease process.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2026–2036)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market’s trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
  • and more…
 

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies – profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
    • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)

Frequently asked questions